IRLAB Therapeutics AB (publ) (IRLAB-A) - Total Assets
Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) holds total assets worth Skr170.55 Million SEK (≈ $18.35 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IRLAB Therapeutics AB (publ) (IRLAB-A) shareholders funds for net asset value and shareholders' equity analysis.
IRLAB Therapeutics AB (publ) - Total Assets Trend (2013–2024)
This chart illustrates how IRLAB Therapeutics AB (publ)'s total assets have evolved over time, based on quarterly financial data.
IRLAB Therapeutics AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
IRLAB Therapeutics AB (publ)'s total assets of Skr170.55 Million consist of 58.4% current assets and 41.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr66.92 Million | 49.1% |
| Accounts Receivable | Skr20.63 Million | 15.1% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr9.79 Million | 7.2% |
| Intangible Assets | Skr46.86 Million | 34.4% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how IRLAB Therapeutics AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IRLAB-A stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IRLAB Therapeutics AB (publ)'s current assets represent 58.4% of total assets in 2024, an increase from 0.0% in 2013.
- Cash Position: Cash and equivalents constituted 49.1% of total assets in 2024, up from 0.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is cash and equivalents at 49.1% of total assets.
IRLAB Therapeutics AB (publ) Competitors by Total Assets
Key competitors of IRLAB Therapeutics AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
IRLAB Therapeutics AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 0.87 | 13.56 |
| Quick Ratio | 1.30 | 0.87 | 13.56 |
| Cash Ratio | 1.22 | 0.77 | 0.00 |
| Working Capital | Skr27.16 Million | Skr-15.37 Million | Skr262.82 Million |
IRLAB Therapeutics AB (publ) - Advanced Valuation Insights
This section examines the relationship between IRLAB Therapeutics AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.88 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -23.1% |
| Total Assets | Skr136.21 Million |
| Market Capitalization | $12.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values IRLAB Therapeutics AB (publ)'s assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: IRLAB Therapeutics AB (publ)'s assets decreased by 23.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for IRLAB Therapeutics AB (publ) (2013–2024)
The table below shows the annual total assets of IRLAB Therapeutics AB (publ) from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr136.21 Million ≈ $14.66 Million |
-23.10% |
| 2023-12-31 | Skr177.12 Million ≈ $19.06 Million |
-45.26% |
| 2022-12-31 | Skr323.56 Million ≈ $34.82 Million |
-31.52% |
| 2021-12-31 | Skr472.45 Million ≈ $50.84 Million |
+27.67% |
| 2020-12-31 | Skr370.07 Million ≈ $39.83 Million |
+77.86% |
| 2019-12-31 | Skr208.07 Million ≈ $22.39 Million |
-7.50% |
| 2018-12-31 | Skr224.94 Million ≈ $24.21 Million |
+38.02% |
| 2017-12-31 | Skr162.97 Million ≈ $17.54 Million |
+44.08% |
| 2016-12-31 | Skr113.11 Million ≈ $12.17 Million |
+11.89% |
| 2015-12-31 | Skr101.09 Million ≈ $10.88 Million |
-5.01% |
| 2014-12-31 | Skr106.43 Million ≈ $11.45 Million |
+325.73% |
| 2013-12-31 | Skr25.00 Million ≈ $2.69 Million |
-- |
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms … Read more